Literature DB >> 7545754

Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders.

F W Bell1, J S Klausner, D W Hayden, E M Lund, B B Liebenstein, D A Feeney, S D Johnston, J L Shivers, C M Ewing, W B Isaacs.   

Abstract

Serum and seminal plasma concentrations or activities of acid phosphatase (AP), prostate specific antigen (PSA), and canine prostate specific esterase (CPSE) were measured in normal dogs, dogs with benign prostatic hyperplasia (BPH), dogs with bacterial prostatitis, and dogs with prostatic carcinoma to determine if these assays would be of value in differentiating dogs with prostatic carcinoma from normal dogs, and dogs with other prostatic disorders. In addition, tissue sections of prostatic adenocarcinomas were stained with antiprostatic AP, anti-CPSE, and anti-PSA antibodies to determine if these would be suitable immunohistochemical markers of prostatic carcinoma. Prostate-specific antigen was not detected in canine serum or seminal plasma. Serum and seminal AP activities did not differ significantly between normal dogs and those with prostatic diseases, or among dogs with different prostatic disorders. Serum CPSE activities were significantly higher in dogs with BPH than in normal dogs. Mean serum CPSE activities in dogs with BPH, bacterial prostatitis, and prostatic carcinoma were not significantly different from each other. Slight to moderate immunohistochemical staining of canine prostatic adenocarcinomas was noted for prostatic AP and PSA; most tumors did not stain for CPSE. These results show that proteins of prostatic origin appear in the serum of dogs as a result of prostatic pathology, especially BPH. Canine prostatic adenocarcinoma does not appear to be associated with significant increases in CPSE or AP activities, possibly because of down-regulation of these enzymes by prostatic carcinoma cells. It is also possible that failure to detect significant differences resulted from limited statistical power for some groups and pairwise analyses because of the small number of dogs evaluated.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545754     DOI: 10.1111/j.1939-1676.1995.tb03288.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  13 in total

1.  Investigation of c-KIT and Ki67 expression in normal, preneoplastic and neoplastic canine prostate.

Authors:  Carlos Eduardo Fonseca-Alves; Priscilla Emiko Kobayashi; Chiara Palmieri; Renée Laufer-Amorim
Journal:  BMC Vet Res       Date:  2017-12-06       Impact factor: 2.741

2.  Evaluation of biomarker canine-prostate specific arginine esterase (CPSE) for the diagnosis of benign prostatic hyperplasia.

Authors:  Dora Pinheiro; João Machado; Carlos Viegas; Cláudia Baptista; Estela Bastos; Joana Magalhães; Maria A Pires; Luís Cardoso; Ana Martins-Bessa
Journal:  BMC Vet Res       Date:  2017-03-23       Impact factor: 2.741

3.  Changes in specific serum biomarkers during the induction of prostatic hyperplasia in dogs.

Authors:  Kamran Golchin-Rad; Asghar Mogheiseh; Saeed Nazifi; Mohammad Saeed Ahrari Khafi; Nooshin Derakhshandeh; Mohammad Abbaszadeh-Hasiri
Journal:  BMC Vet Res       Date:  2019-12-05       Impact factor: 2.741

Review 4.  Highlights on the Canine Prostatic Specific Esterase (CPSE): A diagnostic and screening tool in veterinary andrology.

Authors:  Monica Melandri; Salvatore Alonge
Journal:  Vet Med Sci       Date:  2020-09-02

5.  Concentrations of canine prostate specific esterase, CPSE, at baseline are associated with the relative size of the prostate at three-year follow-up.

Authors:  Bodil S Holst; Sofia Carlin; Virginie Fouriez-Lablée; Sofia Hanås; Sofie Ödling; Liss-Marie Langborg; S J Kumari A Ubhayasekera; Jonas Bergquist; Jesper Rydén; Elin Holmroos; Kerstin Hansson
Journal:  BMC Vet Res       Date:  2021-04-26       Impact factor: 2.741

6.  Establishing an in vivo model of canine prostate carcinoma using the new cell line CT1258.

Authors:  Melani A M Fork; Hugo Murua Escobar; Jan T Soller; Katharina A Sterenczak; Saskia Willenbrock; Susanne Winkler; Martina Dorsch; Nicola Reimann-Berg; Hans J Hedrich; Jörn Bullerdiek; Ingo Nolte
Journal:  BMC Cancer       Date:  2008-08-15       Impact factor: 4.430

7.  Generation and characterisation of a canine EGFP-HMGA2 prostate cancer in vitro model.

Authors:  Saskia Willenbrock; Siegfried Wagner; Nicola Reimann-Berg; Mohammed Moulay; Marion Hewicker-Trautwein; Ingo Nolte; Hugo Murua Escobar
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

8.  Effect of pulsed electromagnetic field therapy on prostate volume and vascularity in the treatment of benign prostatic hyperplasia: a pilot study in a canine model.

Authors:  Raffaella Leoci; Giulio Aiudi; Fabio Silvestre; Elaine Lissner; Giovanni Michele Lacalandra
Journal:  Prostate       Date:  2014-06-09       Impact factor: 4.104

Review 9.  Canine prostate models in preclinical studies of minimally invasive interventions: part II, benign prostatic hyperplasia models.

Authors:  Fei Sun; Claudia Báez-Díaz; Francisco Miguel Sánchez-Margallo
Journal:  Transl Androl Urol       Date:  2017-06

Review 10.  Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?

Authors:  Magdalena Schrank; Stefano Romagnoli
Journal:  Animals (Basel)       Date:  2020-01-05       Impact factor: 2.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.